FDA granted orphan drug designation for Iomab-B, a radioimmunotherapeutic that conditions relapsed and refractory acute myeloid leukemia patients for a hematopoietic stem cell transplant. Actinium Pharmaceuticals Inc., iomab-B’s sponsor, plans to begin a phase III trial in 150 relapsed and refractory AML patients over the age of 55. Iomab-B is a radioimmunoconjugate consisting of BC8,...
In this episode of the Cancer Letter Podcast, all three of The Cancer Letter’s reporters come together to talk about the potential impact of President Donald Trump’s tariffs on cancer care.
